Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

Erasca (NASDAQ: ERAS) is hit with a securities class action after its shares plunged $9.25 (-48%) following Revolution Medicines’ patent infringement claims over Erasca’s pan-RAS molecular glue (ERAS-0015) and reports that a patient died one month after receiving ERAS-0015. The lawsuit seeks to cover investors who bought Erasca common stock between Jan. 14, 2025 and Apr. 26, 2026, keeping legal and clinical risk elevated. The stock drop suggests near-term negative repricing risk for ERAS.

Analysis

ERAS just moved from a single-asset oncology story to a balance-sheet and credibility story. For a pre-revenue biotech, that matters more than the headline drawdown: litigation risk raises the cost of capital, while any safety signal on an investigational program can slow enrollment, spook investigators, and make partners insist on harsher economics. The immediate aftermath is usually dominated by forced de-risking and retail liquidation; over the next 1-3 months the market will focus on whether management can defend the IP, preserve runway, and avoid a financing that locks in dilution.

RVMD is the cleaner relative winner, but not because of direct revenue transfer; it benefits if investors conclude the RAS space is real but the most fragile execution risk is now in the weaker company. That can widen the valuation gap between the category leader and smaller followers, especially if capital markets start rewarding scale, cash, and clinical depth over platform breadth. A second-order effect is sympathy pressure on the broader small-cap oncology basket and on any company marketing a similar mechanism without near-term clinical de-risking.

The contrarian view is that the first move may be partly emotional: patent disputes in biotech often end in licensing or settlement rather than a business-ending injunction, and a single adverse patient event is not yet a program-wide safety verdict. But the longer the dispute drags on, the more likely ERAS becomes a financing candidate rather than a development story. Falsifiers are straightforward: a strong legal response that narrows or neutralizes the claim, clean follow-up safety/efficacy data, or a disclosed runway that removes near-term dilution risk.

Key Decisions for Investors

• Relative-value: long RVMD / short ERAS for 1-3 months to express widening quality gap in the RAS space; best entry on any ERAS reflex bounce. Risk/reward favors ~2:1 if ERAS faces either a legal injunction motion or a dilutive financing.
• If liquidity/borrow is attractive, short ERAS via put spreads rather than outright short to avoid gap risk from legal headlines; target 2-3 month tenor. Falsifier: rapid settlement on non-dilutive terms or unexpectedly strong clinical rebuttal.
• Set an alert on ERAS financing language and cash runway disclosures; if runway is under ~12 months, expect dilution risk to dominate within 1-2 quarters and keep pressure on the stock. This is the key catalyst, not the lawsuit itself.
• Avoid chasing RVMD outright at any price; treat it as a relative hedge or basket long versus XBI rather than a standalone momentum trade. Upside is modest unless the market rerates the entire RAS franchise.
• Watch XBI / small-cap biotech for sympathy weakness over the next 1-4 weeks; if the group underperforms while ERAS remains weak, that confirms a broader repricing of platform-risk names.